Industry Strength Score
55/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
ABVC BIOPHARMA INC (ABVC) Stock Price & Overview
NASDAQ:ABVC • US00091F3047
Current stock price
1.03 USD
-0.04 (-3.74%)
At close:
1.09 USD
+0.06 (+5.83%)
After Hours:
The current stock price of ABVC is 1.03 USD. Today ABVC is down by -3.74%. In the past month the price increased by 6.17%. In the past year, price decreased by -1.9%.
ABVC Key Statistics
52-Week Range0.8801 - 5.48
Current ABVC stock price positioned within its 52-week range.
1-Month Range0.9501 - 1.75
Current ABVC stock price positioned within its 1-month range.
- Market Cap
- 26.203M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.26
- Dividend Yield
- N/A
ABVC Stock Performance
Today
-3.74%
1 Week
-12.71%
1 Month
+6.17%
3 Months
-49.01%
Longer-term
6 Months -63.21%
1 Year -1.90%
2 Years -17.60%
3 Years -84.85%
5 Years N/A
10 Years N/A
ABVC Stock Chart
ABVC Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ABVC. When comparing the yearly performance of all stocks, ABVC is a bad performer in the overall market: 88.12% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
ABVC Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ABVC. ABVC may be in some trouble as it scores bad on both profitability and health.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ABVC Earnings
Next Earnings DateAug 11, 2026
Last Earnings DateApr 28, 2026
PeriodQ3 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %
ABVC Forecast & Estimates
Analysts
Analysts43.33
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A
ABVC Financial Highlights
Over the last trailing twelve months ABVC reported a non-GAAP Earnings per Share(EPS) of -0.26. The EPS increased by 73.56% compared to the year before.
Income Statements
Revenue(TTM)2.00K
Net Income(TTM)-4.91M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -23.16% | ||
| ROE | -40.73% | ||
| Debt/Equity | 0.07 |
Chartmill High Growth Momentum
EPS Q2Q%-339%
Sales Q2Q%-100%
EPS 1Y (TTM)73.56%
Revenue 1Y (TTM)-99.61%
ABVC Ownership
Ownership
Inst Owners3.4%
Shares25.44M
Float20.61M
Ins Owners15.72%
Short Float %1.43%
Short Ratio3.19
ABVC Industry Overview
ABVC operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
27%
Outperformed 27% of sub-industries
3 Month Rank
44%
Outperformed 44% of sub-industries
6 Month Rank
31%
Outperformed 31% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 4.8%
- New Lows
- 3.9%
- Average ROE
- 48.2%
- Average Profit Margin
- 20.9%
- Average Operating Margin
- 33.6%
- Average P/E
- 26.1
- Average Fwd P/E
- 22.4
- Average Debt/Equity
- 2.1
ABVC Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.75 | 349.666B | ||
| AMGN | AMGEN INC | 14.8 | 183.263B | ||
| GILD | GILEAD SCIENCES INC | 14.57 | 160.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.73 | 109.41B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.64 | 77.363B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.13 | 40.311B | ||
| INSM | INSMED INC | N/A | 29.127B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.701B | ||
| NTRA | NATERA INC | N/A | 28.37B | ||
| BIIB | BIOGEN INC | 12.06 | 26.913B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.54 | 24.944B | ||
| INCY | INCYTE CORP | 10.85 | 19.451B | ||
| MRNA | MODERNA INC | N/A | 18.695B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ABVC
Company Profile
ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The company is headquartered in Fremont, California and currently employs 19 full-time employees. The company went IPO on 2004-11-09. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV- 1501, ABV-1519 and ABV-1701. The firm is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine to treat Major Depressive Disorder (MDD). ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). The company has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. The company has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer. The company also focuses on the development of new drugs and medical devices derived from plants.
Company Info
IPO: 2004-11-09
ABVC BIOPHARMA INC
44370 Old Warm Springs Blvd
Fremont CALIFORNIA US
CEO: Howard Doong
Employees: 19
Phone: 15106680881
ABVC BIOPHARMA INC / ABVC FAQ
What does ABVC BIOPHARMA INC do?
ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The company is headquartered in Fremont, California and currently employs 19 full-time employees. The company went IPO on 2004-11-09. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV- 1501, ABV-1519 and ABV-1701. The firm is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine to treat Major Depressive Disorder (MDD). ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). The company has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. The company has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer. The company also focuses on the development of new drugs and medical devices derived from plants.
Can you provide the latest stock price for ABVC BIOPHARMA INC?
The current stock price of ABVC is 1.03 USD. The price decreased by -3.74% in the last trading session.
What is the dividend status of ABVC BIOPHARMA INC?
ABVC does not pay a dividend.
What is the ChartMill technical and fundamental rating of ABVC stock?
ABVC has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How is the valuation of ABVC BIOPHARMA INC (ABVC) based on its PE ratio?
ABVC BIOPHARMA INC (ABVC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.26).
What is ABVC BIOPHARMA INC worth?
ABVC BIOPHARMA INC (ABVC) has a market capitalization of 26.20M USD. This makes ABVC a Nano Cap stock.